Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1

This study has been completed.
Information provided by:
University of Pennsylvania Identifier:
First received: September 20, 2005
Last updated: April 12, 2013
Last verified: June 2010

September 20, 2005
April 12, 2013
April 1998
November 2007   (final data collection date for primary outcome measure)
Alcohol and Cocaine use during the treatment trial period and at the 6- and 12-month follow-up. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00218660 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1
Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence

The purpose of this study is to see whether naltrexone is safe and useful in preventing alcohol relapse, as well as in decreasing craving for alcohol in people with a diagnosis of alcohol and cocaine dependence. Naltrexone is approved by the Food and Drug Administration (FDA) for the treatment of alcohol dependence. However, the medication was not approved as yet at the dosage we will use in this study. The dosage we will use for the study (150 mg), is greater than the recommended dosage from the Physician's Desk Reference (50mg). Unlike other medicines (like Antabuse) useful in the treatment of alcohol dependence, naltrexone will not make you sick if you drink alcohol. Rather, people who are taking this medication have reported that it helps decrease the pleasure associated with drinking for them. This study is being conducted because the medication (Naltrexone) has not been well studied in people with both alcohol and cocaine dependence, so it is still investigational.

We believe that if we can reduce alcohol consumption through naltrexone and psychotherapy, this may lead to reduced cocaine use. We are also conducting this study to test two different types of psychotherapy as a method for reducing cocaine and alcohol use. One type of psychotherapy, CBT, is designed to help people learn to cope with situations that put them at high risk for relapse to cocaine and/or alcohol use. The other type of psychotherapy, BRENDA, will use focuses on strengthening motivation to recover from cocaine and/or alcohol use, and on developing techniques to handle possible barriers to recovery. We seek to enroll 300 patients in the study.

The project will use a 2x2 design to assess the efficacy of naltrexone for treating subjects who are both cocaine and alcohol dependent and who will receive either CBT or BRENDA alone or in combination with naltrexone. There will be 300 DSM-IV cocaine-alcohol dependent male and female subjects randomized to one of four groups (75 subjects per group). Subjects will be randomized to either 150mg/day naltrexone or placebo and to receive either CBT (a type of cognitive behavior therapy derived from relapse prevention principles), or a new primary-care basedmodel, BRENDA, comprised of strategies for enhancing motivation and treatment compliance. All subjects will receive one of the four combinations of medication and psychosocial treatment. The length of the study for each subject includes one week of screening/baseline assessments, 12 weeks of double-blind, placebo-controlled naltrexone treatment combined with one of two psychosocial treatments, and a 6-month and 12-month follow-up visit. Following successful completion of detoxification (abstinence from alcohol and cocaine for 7 days), informed consent will be signed, and Week 1 will be devoted to completing screening and baseline measures. In Week 2, subjects will be randomly assigned to medication/ psychosocial treatment combination. Following completion of the 12-week, double-blind treatment trial, subjects will be evaluated at 6-month and 12-months post-treatment visits.

Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Alcoholism
  • Cocaine Dependence
  • Drug: Naltrexone
    150mg/day Naltrexone
  • Behavioral: BRENDA
    Psychosocial Treatment
  • Behavioral: CBT
    Cognitive Behavioral Therapy
  • Drug: Placebo
    Other Name: 150mg/day Placebo
  • Experimental: 1
    Nal + BRENDA
    • Drug: Naltrexone
    • Behavioral: BRENDA
  • Placebo Comparator: 2
    Placebo + BRENDA
    • Behavioral: BRENDA
    • Drug: Placebo
  • Experimental: 3
    Nal + CBT
    • Drug: Naltrexone
    • Behavioral: CBT
  • Placebo Comparator: 4
    Placebo + CBT
    • Behavioral: CBT
    • Drug: Placebo
Pettinati HM, Kampman KM, Lynch KG, Suh JJ, Dackis CA, Oslin DW, O'Brien CP. Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. J Subst Abuse Treat. 2008 Jun;34(4):378-90. Epub 2007 Jul 30.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
November 2007
November 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and females, 18-65 years old.
  • Meets DSM-IV criteria for current diagnoses of cocaine and alcohol dependence, determined by the SCID.
  • In the past 30 days, S used no less than $200-worth of cocaine and >15 standard alcohol drinks (avg)/week with at least 1 day of 4 or more drinks, determined by the TLFB--adapted to collect daily cocaine use.
  • Successful completion of alcohol detoxification, i.e.,
  • 5 consecutive days of abstinence from cocaine and alcohol, via self-reports and negative urine toxicology screens.
  • Lives a commutable distance to the TRC and agrees to follow-up visits.
  • Understands and signs the consent.

Exclusion Criteria:

  • Abstinent from cocaine or alcohol for 30 days prior to signing consent form. (S may have been institutionalized in the prior month and still be eligible if his/her cocaine and alcohol use that month met inclusion criteria.)
  • Current DSM-IV diagnosis of any substance dependence other than cocaine, alcohol, nicotine, or cannabis determined by the SCID.
  • Evidence of opiate use in the past 30 days, determined by self-report on the SCID or ASI, and/or by a urine drug screen that is positive for opiates at treatment entry.
  • Current treatment with psychotropic medications (excluding short-term use of benzodiazepines for detoxification), including disulfiram.
  • History of unstable or serious medical illness, including need for opioid analgesics.
  • History of epilepsy or seizure disorder.
  • Known severe physical or medical illnesses such as AIDS, active hepatitis, significant hepatocellular injury as evidenced by elevated bilirubin levels, or elevated levels over 4.5x normal of aspartate aminotransferase (AST), and serum glutamic-pyruvic transaminase (SGPT).
  • Current severe psychiatric symptoms, e.g., psychosis, dementia, acute suicidal or homicidal ideation, mania or depression requiring antidepressant therapy, or which would make it unsafe for the patient to participate in the opinion of the primary investigators.
  • Use of an investigational medication in the past 30 days.
  • Female Ss who are pregnant, nursing, or not using a reliable method of contraception. [Note: Criteria 4-10 will be assessed via the medical exam plus results from lab tests.]
18 Years to 65 Years
Contact information is only displayed when the study is recruiting subjects
United States
NIDA-5186-1, P60DA005186, P60-5186-1
Helen Pettinati, Ph.D., University of Pennsylvania Treatment Research Cener
University of Pennsylvania
National Institute on Drug Abuse (NIDA)
Principal Investigator: Charles O'Brien, M.D., Ph.D. University of Pennsylvania
University of Pennsylvania
June 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP